Loading clinical trials...
Loading clinical trials...
Phase III A Prospective, Longitudinal, Rater-blinded Single-arm Study to Evaluate Alemtuzumab as an Effective Treatment in Stabilizing Overall Neurocognitive Function in RRMS Subjects at Specified Timepoints
Conditions
Interventions
Alemtuzumab
Start Date
May 1, 2011
Primary Completion Date
December 1, 2013
Completion Date
March 1, 2014
Last Updated
April 25, 2011
NCT07225504
NCT06276634
NCT06809192
NCT05359653
NCT07426991
NCT07376772
Lead Sponsor
Central Texas Neurology Consultants
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions